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O steosarcoma (OS) is the most common primary malignant bone tumor,  and occurs mainly in 
children and adolescents [1].  Historically,  the clinical 
prognosis of OS improved significantly in the 1970s,  
with the survival rate  reaching 60-70% after the advent 
of high-dose,  multi-agent chemotherapy.  However,  sur-
vival measures have failed to demonstrate any further 
improvements in the prognosis of OS for more than 
30 years,  despite advances in surgical techniques and 
changes in chemotherapy regimens [2 , 3].  To date,  
there are few useful biomarkers for monitoring tumor 
burden and response to treatment in OS.  Salvage che-
motherapy is of limited efficacy,  even after identifying 
relapse [2].  The development of diagnostic and thera-
peutic strategies based on a thorough understanding of 
the molecular basis of metastasis is thus required to 
improve patient survival.
MicroRNAs (miRNAs),  a class of small noncoding 
RNAs,  are involved in the post-translational regulation 
of gene expression via their ability to inhibit the stability 
and translation of messenger RNA (mRNA) [4].  miRNAs 
play important roles in a variety of physiological 
and pathological processes by modulating the expres-
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Although there is considerable evidence indicating that the dysregulation of microRNAs (miRNAs) in malig-
nant tumors plays a role in tumor development,  the overall function of miRNAs and their clinicopathological 
significance are not well understood.  In this retrospective analysis of 45 biopsy specimens from osteosarcoma 
(OS) patients,  we investigated the functional and clinical significance of miR-25-3p in OS,  which we previously 
identified as a highly expressed miRNA in OS patients’ serum.  We observed that miR-25-3p dysregulation in 
human OS tissues was negatively correlated with the clinical prognosis,  whereas the expression level of its target 
gene,  Dickkopf WNT Signaling Pathway Inhibitor 3 (DKK3),  was positively correlated with the clinical prognosis.  
Endogenous miR-25-3p upregulation promoted tumor growth,  invasion,  and drug resistance,  which was con-
sistent with DKK3 silencing in OS cells.   In addition,  secretory miR-25-3p was embedded in tumor-derived 
exosomes,  where it promoted capillary formation and the invasion of vascular endothelial cells.  Overall,  our 
results show that miR-25-3p has intracellular and extracellular oncogenic functions as well as clinicopathological 
relevance in OS,  indicating its potential as a novel diagnostic and therapeutic tool for the clinical management 
of this disease.
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sion of their multiple target genes [4 , 5].  To date,  
miRNA dysregulation has been documented in malig-
nant tumors,  demonstrating that miRNAs can have 
either an oncogenic or tumor suppressive function 
[6 , 7].  In addition,  miRNAs were recently  demon-
strated to be secreted into the circulation in a cell-free 
form [8 , 9].  
Despite the presence of RNase activity in human 
blood,  circulating miRNAs are detectable in extracellu-
lar vesicles such as exosomes,  which are secreted from 
tumor cells and play a biological and pathological role in 
intercellular communication within the tumor micro-
environment and promote cell motility and invasion in 
cancer [10].  The demonstration of circulating miRNA 
levels in the blood or urine of patients may present a 
novel approach to predicting clinical behavior and ther-
apeutic responses [9 , 11].  We previously identified the 
secretion of the miRNA miR-25-3p in OS cells,  and 
miR-25-3p was also detected in the serum of OS patients 
[12].  Serum miR-25-3p at the pretreatment status miR-
25-3p levels of the OS patients were significantly cor-
related with patient prognosis [12].
However,  the clinicopathological significance and 
intracellular and extracellular functions of miR-25-3p 
dysregulation in OS have been unclear,  and few reports 
have documented the functional and clinical value of 
miR-25-3p in the management of malignant tumors.  In 
the present study,  we investigated the functional and 
clinicopathological significance of intracellular and 
extracellular miR-25-3p dysregulation in OS toward an 
understanding of the overall function of miR-25-3p in 
tumor progression.
Materials and Methods
Human tissues. The study protocol was approved 
by the Institutional Review Board of Okayama 
University Hospital (No. 1509-037).  All patients pro-
vided written,  informed consent authorizing the collec-
tion and use of their samples for research purposes.  
Tumor samples from OS patients were collected 
between 2000 and 2015 at the Okayama University 
Hospital.
Cell lines and cell culture. The human OS cell 
lines 143B and U2OS were purchased from the 
American Type Culture Collection (Manassas,  VA,  
USA).  Human mesenchymal stem cells (hMSCs) were 
purchased from Lonza (Walkersville,  MD,  USA).  
Human umbilical vein endothelial cells (HUVECs) were 
purchased from PromoCell (Heidelberg,  Germany).  
143B and U2OS cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) (Life Technologies,  
Grand Island,  NY,  USA).  All media were supple-
mented with 10% fetal bovine serum (FBS; Life 
Technologies),  50 units/ml penicillin,  and 50 μg/ml 
streptomycin (Life Technologies).  Cells were main-
tained under 5% CO2 in a humidified incubator at 37°C.
Exosome isolation. Exosomes were purified from 
the culture medium supernatant as described previously 
[14].  The supernatant was ultracentrifuged using an 
Optima TL-100 ultracentrifuge (Beckman Coulter,  
Fullerton,  CA,  USA) at 110,000 g for 70 min to pellet 
the exosomes.  The pellet was washed in phosphate- 
buffered saline (PBS) to eliminate contaminating pro-
teins,  and centrifuged again at 110,000 g for 70 min.  
The PBS was removed and the exosomes were re-sus-
pended in 100 µl of PBS.
RNA extraction and RT-PCR. Total RNA 
(including miRNA) was extracted using an miRNeasy 
mini Kit (Qiagen,  Valencia,  CA,  USA) according to the 
manufacturer’s instructions.  RNA samples were reverse 
transcribed using the TaqMan MicroRNA Reverse 
Transcription Kit (Applied Biosystems,  Foster,  CA,  
USA).  For mRNA detection,  total RNA was reverse 
transcribed using a PrimeScript RT Reagent Kit (Takara,  
Tokyo,  Japan) according to the manufacturer’s protocol.  
Quantitative polymerase chain reaction (PCR) was per-
formed on an Agilent Mx3000P QPCR System (Agilent 
Technologies,  Santa Clara,  CA,  USA) using TaqMan 
2 × Universal PCR Master mix and each primer.  Data 
obtained from RT-PCR were analyzed using the 2−∆∆Ct 
method.  The miRNA expression levels were normalized 
using the miRNA cel-miR-39 for exosomes and the 
small non-coding RNA RNU6B  for tumor cells,  and 
the mRNA expression levels were normalized using 
GAPDH.
Western blots. Total protein was extracted from 
the cells using Mammalian Protein Extraction Buffer 
(GE Healthcare,  Chicago,  IL,  USA).  Fifteen μg of each 
protein extract was separated on Mini-PROTEAN® 
TGX gels (Bio-Rad Laboratories,  Hercules,  CA,  USA) 
and transferred onto Immun-Blot® PVDF membranes 
(Bio-Rad).  The membranes were probed with the fol-
lowing primary antibodies: anti-CD9 mouse monoclo-
nal antibody (Abcam,  Cambridge,  UK),  anti-CD81 
mouse monoclonal antibody (Santa Cruz Biotechnology,  
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Santa Cruz,  CA,  USA),  anti-β-actin mouse monoclo-
nal antibody (Sigma-Aldrich,  St.  Louis,  MO,  USA),  
and anti-DKK3 rabbit polyclonal antibody (Abcam).  
The secondary antibody was IRDye® 800CW anti-rabbit 
IgG or IRDye® 680RD anti-mouse IgG (LI-COR,  
Lincoln,  NE,  USA).
Transfection with synthetic miRNAs, LNAs, and 
siRNAs. Synthetic hsa-miRs (pre-miR-hsa-miR-25 
and negative control; Life Technologies) and locked 
nucleic acids (LNAs) (LNA-antimiR-25-3p and scram-
ble control; Gene Design,  Ibaraki,  Japan) were trans-
fected at a final concentration of 30 nM each with the 
use of the transfection agent DharmaFECT 1 (GE 
Healthcare).  Synthetic siRNAs (Life Technologies) were 
transfected into the cells at a final concentration of 
10 nM each using DharmaFECT 1 (GE Healthcare).
Prediction of miRNA target genes. The miRNA 
analysis web (http://www.microrna.org/) was used to 
identify candidate miRNAs.  This web-based tool is 
integrated with three of the most commonly used target 
gene prediction algorithms: miRanda,  MiRtarget2 and 
TargetScan.
Cell proliferation and cytotoxicity assays. Cell 
proliferation rates and cell viability were used as indica-
tors of the relative sensitivity of the cells to doxorubicin,  
cisplatin,  methotrexate,  and docetaxel.  Measurements 
were determined using the WST-1 Proliferation Assay 
(Sigma-Aldrich) per the manufacturer’s instructions.  
Cells were seeded in 96-well plates after 24-h transfec-
tion,  and treated with varying doses of doxorubicin 
(Sigma-Aldrich),  cisplatin (Enzo Life Sciences,  
Farmingdale,  NY,  USA),  methotrexate (Sigma-
Aldrich),  or docetaxel (Sigma-Aldrich) for 72 h.  
Absorbance was measured at 450 nm with a reference 
wavelength at 630 nm by a microplate reader (Bio-
Rad).  The relative number of viable cells is expressed as 
the percent of viable cells.
Cell migration and invasion assay. Cell invasion 
and migration were examined with 24-well BD BioCoat 
invasion chambers with and without Matrigel matrix 
(BD Biosciences,  San Jose,  CA,  USA).  Cells of the 
lines 143B,  U2OS and HUVECs were trypsinized and 
seeded in chambers 48 h after transfection.  The cells 
were subsequently suspended in medium without FBS 
and added to the upper chamber.  Medium with 10% 
FBS was added to the lower chamber.  After a 24-h 
incubation,  the cells on the upper side were removed,  
and the filters were fixed in methanol and stained with 
Hemacolor® solution 3 (Merck,  Darmstadt,  Germany).  
The number of cells was counted in 6 separated high-
power fields.
Luciferase assay. First,  143B cells were cotrans-
fected with the pGL3-DKK3-3’ untranslated region 
(UTR) or with the pGL3-DKK3-3’UTR Mut plasmid,  
the phRL-SV40 control vector (Promega,  Fitchburg,  
WI,  USA),  and 30 nM miR-25-3p mimic or AccuTargetTM 
miRNA mimic negative control #1 (Bioneer,  Alameda,  
CA,  USA) using Lipofectamine® 3000 (Invitrogen,  
Waltham,  MA,  USA).  After transfection for 48 h,  we 
determined the renilla and firefly luciferase activities 
using a Dual Luciferase Reporter Gene Assay kit 
(Promega) according to the manufacturer’s instruc-
tions.  Luciferase activity was detected by a FlexStation 
3 microplate reader (Molecular Devices,  Sunnyvale,  
CA,  USA).  The firefly luciferase activity of each sample 
was normalized using the renilla luciferase activity.
Immunohistochemistry. Slides were heated for 
antigen retrieval in 10 mM sodium citrate (pH 6.0),  
followed by incubation with polyclonal goat anti-hu-
man DKK3 (Abcam) or isotype-matched control anti-
bodies overnight at 4°C.  Immunodetection was per-
formed using Histofine anti-goat IgG (Nichirei,  Tokyo,  
Japan) and the DAB substrate kit (Nichirei) according 
to the manufacturer’s instructions.  Sections were coun-
terstained with hematoxylin to create contrast.  The 
immunohistochemical (IHC) score was defined as the 
proportion of tumor cells with stained cell membrane:  
negative,  0-49%; focal,  50-79%; diffuse,  80-100%.
Tube formation assay. HUVECs were plated on 
top of Matrigel and treated with exosomes (50 ng per 
well) derived from OS cells 48 h after transfection.  Tube 
formation was quantified by counting the branch point 
number in three wells after 24 h.  The average number of 
each group was calculated and normalized to the aver-
age number of the control group.
Statistical analysis. Experiments were repeated 
at least 3 times.  Statistical analyses were performed 
using SPSS ver.  23 software (SPSS,  Chicago,  IL,  USA).  
Student’s two-tailed t-test was used for comparisons of 
pairs of groups.  For comparisons of more than 2 
groups,  we performed a one-way analysis of variance 
(ANOVA).  The differences in miR-25-3p expression 
among different clinicopathological data were analyzed 
by the chi-squared test.  The Kaplan-Meier method and 
the log-rank test were used to compare the survival of 
patients.  P-values < 0.05 were considered significant.
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Results
The dysregulated miR-25-3p expression levels in OS 
tissue specimens were negatively correlated with the 
patient prognosis. To investigate the clinical signifi-
cance of miR-25-3p expression levels in OS tissue speci-
mens,  we performed a Kaplan-Meier analysis on the 
RT-PCR results of 45 fresh frozen human biopsy speci-
mens.  High miR-25-3p expression in the pretreatment 
OS tissues was significantly correlated with poor overall 
survival (p = 0.004,  log-rank test; Fig. 1A).  High miR-
25-3p levels were also correlated with poor metasta-
sis-free survival (p = 0.005,  log-rank test; Fig. 1B).  The 
clinicopathological features of the patients in relation to 
the expression of miR-25-3p are summarized in Table 1.  
The statistical analysis revealed a significant correlation 
between high-miR-25-3p expression and the presence of 
metastasis (p = 0.014) and the oncologic outcome 
(p = 0.003).  These data were consistent with those 
obtained previously for circulating miR-25-3p [12],  
indicating that both cellular and circulating miR-25-3p 
expression levels are significantly correlated with the 
prognosis of OS patients.
miR-25-3p regulates lethal phenotypes of OS cells.
To investigate the role of miR-25-3p in OS cells,  we per-
formed a functional analysis by altering miR-25-3p 
expression.  Because miR-25-3p was confirmed to be 
expressed at a higher level in OS cells compared to nor-
mal cells [12] (Fig. 2A),  we performed functional anal-
ysis using locked nucleic acids (LNAs).  LNA-antimiR-
25-3p suppressed the miR-25-3p expression in OS cells 
(Fig. 2B).  The proliferation assays revealed that miR-
25-3p silencing suppressed the tumor growth ability in 
OS cells (Fig. 2C).  In addition,  cellular invasiveness was 
also reduced by LNA-antimiR-25-3p (Fig. 2D).  
Interestingly,  miR-25-3p silencing improved the multi-
drug resistance in OS cells (Fig. 2E).  These data 
revealed that miR-25-3p is a potential oncogenic miRNA 
in OS and contributes to the development of OS.
DKK3, a direct target of miR-25-3p, regulates cellu-
lar proliferation and invasion in OS. We screened 
the mRNA targets of miR-25-3p by using the in silico 
prediction algorithms miRanda,  MiRtarget2 and 
TargetScan to determine the potential downstream 
pathway regulated by miR-25-3p.  Among the 122 down-
stream targets of miR-25-3p revealed by both algorithms,  
DKK3 was identified as a miR-25-3p target (Fig. 3A).  
DKK3 plays an important role in the Wnt-β catenin sig-
naling pathway,  which is inactive in OS [13].  DKK3 
expression was inversely correlated with miR-25-3p in 
OS cells,  confirming increased DKK3 levels by miR-
25-3p silencing (Fig. 3B).
To validate whether DKK3 is regulated by miR-25-3p,  
we cloned the 3’UTR fragment containing the putative 
miR-25-3p binding site downstream of a luciferase cod-
ing sequence,  and the luciferase reporter and miR-
25-3p oligos were cotransfected into U2OS cells.  The 
luciferase activity levels were approximately 72% lower 
in the cells cotransfected with miR-25-3p compared to 
the cells cotransfected with miR-NC oligos (Fig. 3C).  We 
evaluated the functional consequences of silencing 
DKK3 expression by using siRNA (Fig. 3D).  Silencing 
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Fig.  1　 Clinical relevance of miR-25-3p expression in OS.  A,  Kaplan-Meier survival curves for overall survival according to miR-25-3p 
expression (log-rank test,  p=0.004); B,  Kaplan-Meier survival curves for metastasis-free survival according to miR-25-3p expression (log-
rank test,  p=0.005).
the DKK3 expression promoted the migration and inva-
sion of the OS cells,  but did not affect the drug resis-
tance (Fig. 3E , F).  Collectively,  these results suggest 
that DKK3,  a direct target of miR-25-3p,  could act to 
prevent tumor growth and metastasis.
The DKK3 expression levels in the OS tissues were 
positively correlated with the patient prognosis. To 
determine the clinicopathological significance of DKK3,  
we performed a statistical analysis of the DKK3 expres-
sion in OS tissues.  Immunohistochemical staining 
revealed DKK3 to be diffusely positive in 55%,  focally 
positive in 6%,  and negative in 39% of the diagnostic 
incisional biopsy specimens,  with DKK3 localized to 
the cytoplasm in the positive cases (Fig. 4A).  The prog-
nosis of the patients whose biopsy specimens were neg-
ative for DKK3 was poor,  with 57% of these patients 
dying of the disease.  Our Kaplan-Meier analysis of the 
RT-PCR results revealed that the DKK3 expression levels 
were significantly correlated with the patients’ progno-
ses.  Low DKK3 expression was significantly correlated 
with poor overall survival (p = 0.022,  log-rank test) and 
poor disease-free survival (p=0.017,  log-rank test) 
(Fig.4B,C).  These data show the clinicopathological 
significance of DKK3 to be inversely correlated with that 
of miR-25-3p,  corresponding to the demonstrated func-
tional relationship between miR-25-3p and its target.
Secretory miR-25-3p is embedded in OS-derived 
exosomes and mediates angiogenesis. We previously 
observed that miR-25-3p was released into the extracel-
lular space in OS cells [12].  Here,  to examine the deliv-
ery of secretory miR-25-3p into extracellular fluid,  we 
purified tumor-derived exosomes and analyzed the 
miR-25-3p expression in exosome fractions.  Scanning 
electron microscopy (SEM) revealed that the exosomes 
had a round shape with 40-100-nm-sized membrane 
vesicles (Fig. 5A).  A nanoparticle tracking analysis of 
the purified exosomes revealed a fraction containing 
nanoparticles with a peak at 101 nm (Fig. 5B).
Our western blot analysis con-
firmed the expression of common 
exosomal surface markers,  CD9 
and CD81,  in the exosome frac-
tions (Fig. 5C).  The RT-PCR 
revealed higher miR-25-3p expres-
sion levels in the tumor-derived 
exosome fractions compared to the 
exosome fractions from the hMSCs 
(Fig. 5D).  These data suggest that 
secretory miR-25-3p in extracellular 
fluid may acquire stability via 
encapsulation by OS-derived exo-
somes.  In addition,  the capillary 
formation of HUVECs was signifi-
cantly enhanced by the addition of 
OS-derived exosomes (Fig.5E).  
Silencing of the miR-25-3p in 
HUVECs decreased the capillary 
formation; however,  the addition 
of OS-derived exosomes restored 
the capillary formation in silenced 
HUVECs (Fig. 5F),  suggesting that 
the transport of OS-derived exo-
somes containing miR-25-3p to 
endothelial cells may disrupt their 
microenvironment and promote OS 
development.
Finally,  increased miR-25-3p 
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Table 1　 Patient characteristics
Factor No. of patients
miR-25-3p expression
p-value
Low High
Age at diagnosis (yrs): 0.229
0-10  3  3  0
11-20 16  8  8
≥21 26 17  9
Gender: 0.258
Male 20 14  6
Female 25 14 11
Location: 0.316
Femur 22 15  7
Tibia  6  4  2
Humerus  3  2  1
Others 14  7  7
Histological subtype: 0.398
Conventional 34 22 12
Other 11  6  5
Response to chemotherapy: 0.287
<90% 19 12  7
≥90% 11  5  6
Local recurrence: 0.538
Yes  7  4  3
No 38 24 14
Distant metastasis: 0.014
Yes 21  9 12
No 24 19  5
Oncologic outcome: 0.003
CDF/NED 26 21  5
DOD 19  7 12
CDF,  continuous disease-free; NED,  no evidence of disease; DOD,  dead of disease.
expression promoted the invasion and migration of 
HUVECs,  whereas miR-25-3p silencing reduced these 
HUVEC phenotypes (Fig. 5G).  These data suggest that 
extracellular miRNAs embedded in secretory exosome 
vesicles could be delivered to the tumor microenviron-
ment and act as physiologically functional molecules to 
promote tumor progression.
Discussion
Accumulating evidence suggests that dysregulated 
miRNAs are involved in the oncogenesis,  maintenance,  
and development of human malignant tumors [6 , 7].  In 
addition,  cell-free circulating miRNAs have been iden-
tified in patients with malignant tumors and may func-
tion in communication with the tumor microenviron-
ment,  indicating that they could be used as novel 
biomarkers in tumor diagnosis and monitoring [14].  
However,  few reports have addressed the clinicopatho-
logical significance and functional relevance of single 
dysregulated specific miRNAs in tumor development.
Ma and colleagues were the first to report an aspect 
of the functional significance of miRNAs by showing 
that the overexpression of a specific miRNA,  miR-10b,  
contributed to the development of breast cancer metas-
tasis [15].  In addition,  oncogenic miR-10b secreted by 
breast cancer cells has been shown to suppress the pro-
tein level of its target genes,  such as HOXD10 and KLF4,  
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in recipient cells,  which can lead to a favorable envi-
ronment for breast cancer development and progres-
sion [16].  However,  miR-10b has rarely been reported 
to be present in the circulation and to have potential as 
a breast cancer biomarker.  miR-21,  an oncomiR,  stim-
ulates the invasion,  intravasation,  and metastasis of 
colorectal cancer [17].  Serum miR-21 is a promising 
biomarker for the early detection and prognosis of col-
orectal cancer [18],  but the extracellular function of 
miR-21 in colorectal cancer is not fully understood.  
Our present findings demonstrated that miR-25-3p had 
functional and clinical significance in the intracellular 
and extracellular regions of OS cells and that it has a role 
in the promotion of tumor progression and develop-
ment,  suggesting that miR-25-3p could have potential as 
a diagnostic biomarker and a therapeutic target in OS 
patients.
We also observed that miR-25-3p affected not only 
the proliferative and invasive abilities of OS cells,  but 
also their drug resistance.  These phenotypes are consis-
tent with the lethal phenotypes of tumor-initiating cells 
(TICs),  which are designated cancer stem cells (CSCs).  
The hallmarks of TICs are not only their self-renewal 
ability,  but also their resistance to conventional chemo-
therapeutic agents and high metastatic potential 
[19 , 20].  Recent studies have shown that miRNAs are 
associated with TIC phenotypes via their ability to 
simultaneously regulate their various target genes 
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Fig.  3　 Dickkopf-3 (DKK3) is a direct target of miR-25-3p.  A,  Alignments of DKK3-3’UTR,  hsa-miR-25-3p,  and DKK3-3’UTR mut,  
in which the complementary sites for the seed region of miR-25-3p are indicated; B,  Relative DKK3 expression in OS cells treated with 
LNA-NC or LNA-antimiR-25-3p; C,  Luciferase activities of 143B cells co-transfected with miR-25-3p oligonucleotides and wild-type (wild) 
or mutant (mut) reporter vectors of DKK3; D,  Western blot analysis of DKK3 expression after negative control siRNA (siNC) or siDKK3 
transfection into 143B and U2OS cells,  respectively; E,  Drug sensitivity according to DKK3 expression in the presence of methotrexate,  
doxorubicin,  cisplatin,  or docetaxel; F,  Invasion assays performed using 143B and U2OS cells at 24 h post-transfection with siNC or 
siDKK3.  Scale bar,  100 μm.  Columns,  mean of at least three independent experiments.  Bars,  SEM.  ＊p<0.05, ＊＊p<0.01.
[21 , 22].  miR-34a,  a p53 target,  is reported to be a key 
negative regulator of prostate CSCs with a CD44-positive 
phenotype,  which are responsible for the clonogenic 
expansion,  tumor regeneration,  and metastasis of 
prostate cancer [21].  In addition,  let-7 is a master reg-
ulator of the CD44+/CD24−/low cell population,  a breast 
CSC fraction with a markedly high TIC [23].
Among these TIC phenotypes,  the most important 
clinical phenotype is drug resistance.  In the present 
study,  we did not investigate the relevance of TICs in 
osteosarcoma; however,  miR-25-3p,  which can regu-
late drug resistance,  could constitute a new therapeutic 
target for this cancer,  and drugs targeting this miRNA 
could be used in combination with conventional thera-
peutic drugs.  Since LNAs are currently undergoing 
phase II clinical trials for the treatment of hepatitis [24],  
it is to be expected that similar strategies could be used 
to develop miRNA therapeutics for the treatment of 
malignant diseases.
Several studies have demonstrated the contribution 
of exosomal miRNAs to cancer metastasis [25 , 26].  
miR-181c promotes the destruction of the blood-brain 
barrier (BBB) by mediating the abnormal localization of 
actin via its ability to downregulate its target gene,  
PDPK1 [26].  miR-210,  which is released by metastatic 
breast cancer cells,  is transported to endothelial cells via 
cancer-derived exosomes and suppresses the expression 
of specific target genes,  resulting in enhanced angio-
genesis [27].  In the present study,  miR-25-3p was 
secreted by OS cells and induced the formation and 
migration of vascular endothelial cells.  Although the 
effects of miR-25-3p have not yet been demonstrated in 
vivo,  miR-25-3p,  which is also upregulated in OS cells,  
altered the surrounding tumor microenvironment and 
stimulated tumor progression.  The molecular mecha-
nism linking OS-secreted exosomal miR-25-3p to the 
microenvironment of the lungs,  a common site of dis-
tant metastasis,  remains unclear and requires further 
exploration.  A broad understanding of all of the func-
tions of oncomiRs in tumor development will provide 
insights into how they could be used to develop new 
novel diagnostic and therapeutic approaches to malig-
nant diseases.
Overall,  our present findings demonstrate the clini-
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Fig.  4　 Clinicopathological signiﬁcance of DKK3 expression.  A,  Immunohistochemical staining of DKK3 and hematoxylin and eosin 
staining of OS biopsy specimens.  Scale bar,  50 μm; B,  Kaplan-Meier survival curves for overall survival according to DKK3 expression 
(log-rank test,  p=0.022); C,  Kaplan-Meier survival curves for metastasis-free survival according to DKK3 expression (log-rank test,  
p=0.017).
copathological and functional significance of intracel-
lular and extracellular miR-25-3p in OS.  Intracellular 
miR-25-3p contributed to cellular proliferation,  inva-
sion,  and drug resistance,  which are lethal OS pheno-
types.  Extracellular miR-25-3p,  which was enriched in 
OS-derived exosomes,  was transported to endothelial 
cells and stimulated angiogenesis.   The levels of circu-
lating and intracellular miR-25-3p were significantly 
correlated with a poor prognosis in the present series of 
OS patients.  By contrast,  the expression of the Wnt 
signaling inhibitor DKK3,  a miR-25-3p target,  was cor-
related with a good prognosis in the OS patients.  These 
findings contribute to our understanding of the intra-
cellular and extracellular functions of dysregulated 
miRNAs in tumor biology and suggest that these func-
tions could be analyzed in liquid biopsies and developed 
to provide novel therapeutics for OS patients.
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Fig.  5　 Exosome-embedded secretory miR-25-3p aﬀects function of normal vascular endothelial cells.  A,  SEM image of puriﬁed exo-
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and U2OS cells; D,  RT-PCR analysis of miR-25-3p expression in secreted exosomes derived from MSC and OS cells; E,  HUVECs tube 
forming assay with or without exosomes derived from OS cells.  Scale bar,  50 μm; F,  Tube formation analysis with alteration of miR-
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